Enanta Pharmaceuticals, Inc. — Form 10-Q Summary
Business context and reporting period
Research and development-focused biotechnology company developing infectious-disease therapies, including hepatitis C virus (HCV) candidates and Bicyclolide antibiotics. This unaudited report covers the quarter and six months ended March 31, 2014; the fiscal year ends September 30. Enanta had no approved products and no product-sale or royalty revenue.
Financial performance and position
| Metric | Three months ended March 31, 2014 | Six months ended March 31, 2014 |
|---|---|---|
| Revenue | $2.16 million | $3.05 million |
| Research and development expense | $4.72 million | $8.99 million |
| General and administrative expense | $2.57 million | $4.65 million |
| Operating loss | $5.13 million | $10.58 million |
| Net loss | $5.20 million | $10.57 million |
| Net loss per common share, basic and diluted | $0.28 | $0.58 |
At March 31, cash and cash equivalents were $18.1 million, marketable securities were $83.9 million, and total cash, cash equivalents and investments were approximately $102.0 million. Total assets were $108.3 million; current assets were $99.3 million and current liabilities $4.4 million. Total liabilities were $6.6 million. The company reported no debt outstanding. No meaningful product gross margin is reported because there were no product sales.
For the six months, operating cash use was $10.0 million; investing activities provided $18.6 million, primarily from marketable-security maturities and sales; financing activities provided $0.6 million, principally option exercises. Cash and cash equivalents increased $9.2 million to $18.1 million.
Material changes versus prior comparable periods
- Quarterly revenue rose to $2.16 million from $1.20 million, entirely from the NIAID contract in 2014; the 2013 quarter also included Novartis research revenue.
- Six-month revenue fell to $3.05 million from $29.06 million. The prior-year period included $15 million in AbbVie and $11 million in Novartis milestones; 2014 revenue was NIAID contract revenue.
- Quarterly R&D expense increased about $1.0 million, principally from antibiotic-program clinical-trial costs and early-stage discovery. Six-month R&D increased about $0.5 million.
- G&A rose $1.1 million for the quarter and $2.0 million for six months, reflecting higher stock-based compensation and public-company insurance, accounting and legal costs.
- The company moved from $19.1 million of operating cash generation in the prior-year half to $10.0 million of operating cash use in the current half, largely reflecting the absence of prior-year milestone receipts.
Outlook, commentary, risks and unusual items
- Management expected approximately $30 million of R&D expense for fiscal 2014, excluding collaborators’ development costs, and anticipated higher future R&D as independent programs advance. It expected G&A to increase with expanded operations and public-company costs.
- Management stated that March 31 resources were expected to fund anticipated cash requirements for at least 24 months; this is a forward-looking estimate subject to risks and uncertainties.
- After quarter-end, Enanta earned two $20 million AbbVie milestones: one for a U.S. regulatory filing in April and one for an EU filing in May. The company expected collection before June 30, 2014. These amounts were not included in March 31 quarter revenue.
- Enanta remained dependent on AbbVie and Novartis for partnered HCV development and potential future milestones and royalties; partner decisions, regulatory outcomes, competition and product commercialization are outside Enanta’s control. Novartis research funding had ended in August 2013.
- NIAID had committed approximately $23.5 million for EDP-788 development, but further funding depended on options exercised at NIAID’s discretion and government appropriations. The contract could be terminated, and costs are subject to government audit.
- Key risks include clinical and regulatory failure or delay, rapidly evolving HCV competition, uncertain partner and government funding, intellectual-property claims, and the possibility of needing additional capital. The company had an accumulated deficit of $118.0 million and a full valuation allowance against deferred tax assets; it planned to reassess realizability after the subsequent $40 million of milestone revenue.
- Management reported effective disclosure controls and no material change in internal control over financial reporting during the quarter. No threatened or pending litigation was reported.
Important facts for investors to verify
- Whether the $40 million of post-quarter AbbVie milestones was collected as expected and how it affects subsequent-period revenue, cash and tax-asset assessments.
- Progress, regulatory decisions and commercialization prospects for AbbVie’s HCV regimen, and the contractual allocation of regimen sales used to calculate Enanta royalties.
- Novartis’s continued development of EDP-239 and the status and timing of the next $15 million Phase 2 milestone.
- NIAID’s future funding-option decisions and their effect on EDP-788 development and Enanta’s net costs.
- Actual R&D spending, cash runway and financing needs compared with management’s fiscal 2014 expense estimate and 24-month liquidity outlook.